Systems, methods, and kits for diagnostics and treatment of viral respiratory infection

Abstract

The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

1 . A method for treating a patient with or a patient at risk of developing an influenza infection, wherein the method comprises administering a composition to the patient, wherein the composition comprises an anti-androgen. 
     
     
         2 . The method of  claim 1 , wherein the anti-androgen is any one or combination of: cyproterone acetate, megestrol acetate, chlormadinone acetate, spironolactone, medrogestone, oxendolone, osaterone, bifluranol, finasteride, dutasteride, flutamide, bicalutamide, nilutamide, topilutamide, enzalutamide, apalutamide, dienogest, drospirenone, medrogestone, nomegestrol acetate, promegestone, trimegestone, ketoconazole, abiraterone acetate, seviteronel, aminoglutethimide, epristeride, alfaestradiol, isotretinoin, saw palmetto, darolutamide, galeterone, proxalutamide, triptorelin pamoate, allylestrenol, chlormadinone acetate or degarelix. 
     
     
         3 . The method of  claim 1 , wherein the method further comprises administering an anti-thyroid medication, a thyroid receptor inhibitor, a TGF-β inhibitor or a combination thereof. 
     
     
         4 . The method of  claim 3 , wherein the anti-thyroid medication is selected from sodium iodide, potassium iodide, colloidal iodine, tapazole, methimazole, sodium iodide-i-131, Iodotope, iosat, Northyx, Tapazole, Propylthiouracil, PropylThyracil, PTU, SSKI, ThyroSafe, ThyroShield, iOSAT, Sodium iodide 131I, Hicon or a combination thereof. 
     
     
         5 . The method of  claim 3 , wherein the thyroid receptor inhibitor is selected from NH-3, tetraiodothyroacetic acid or a combination thereof. 
     
     
         6 . The method of  claim 3 , wherein the TGF-β inhibitor is selected from M7824, bintrafusp alfa, galunisertib, SAR439459, NIS793, PF-06952229, vactosertib, AVID200, ARGX-115, ABBV-151, trabedersen, VTX-002, ACE-1332, SRK-181 or a combination thereof. 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . A method for treating a patient with or a patient at risk of developing an influenza infection, wherein the method comprises administering to the patient an anti-androgen, an anti-thyroid medication, a thyroid receptor inhibitor, a TGF-β inhibitor or a combination thereof. 
     
     
         10 . The method of  claim 9 , wherein the anti-thyroid medication is selected from sodium iodide, potassium iodide, colloidal iodine, tapazole, methimazole, sodium iodide-i-131, Iodotope, iosat, Northyx, Tapazole, Propylthiouracil, PropylThyracil, PTU, S SKI, ThyroSafe, ThyroShield, iOSAT, Sodium iodide 131I, Hicon or a combination thereof. 
     
     
         11 . The method of  claim 9 , wherein the thyroid receptor inhibitor is selected from NH-3, tetraiodothyroacetic acid or a combination thereof. 
     
     
         12 . The method of  claim 9 , wherein the TGF-β inhibitor is selected from M7824, bintrafusp alfa, galunisertib, SAR439459, NIS793, PF-06952229, vactosertib, AVID200, ARGX-115, ABBV-151, trabedersen, VTX-002, ACE-1332, SRK-181 or a combination thereof. 
     
     
         13 . The method of  claim 9 , wherein the anti-androgen is any one or combination of: cyproterone acetate, megestrol acetate, chlormadinone acetate, spironolactone, medrogestone, oxendolone, osaterone, bifluranol, finasteride, dutasteride, flutamide, bicalutamide, nilutamide, topilutamide, enzalutamide, apalutamide, dienogest, drospirenone, medrogestone, nomegestrol acetate, promegestone, trimegestone, ketoconazole, abiraterone acetate, seviteronel, aminoglutethimide, epristeride, alfaestradiol, isotretinoin, saw palmetto, darolutamide, galeterone, proxalutamide, triptorelin pamoate, allylestrenol, chlormadinone acetate or degarelix. 
     
     
         14 . (canceled) 
     
     
         15 . The method of  claim 1 , wherein the patient also has prostate cancer. 
     
     
         16 . The method of  claim 9 , wherein the method further comprises administering agents that counter the effect of androgens. 
     
     
         17 . The method of  claim 16 , wherein the agents that counters the effect of androgens are sex hormone-binding globulin (SHBG) stimulators. 
     
     
         18 . The method of  claim 9 , wherein the method further comprises administering an antigonadotropin. 
     
     
         19 . The method of  claim 9 , wherein the method further comprises administering a mineralocorticoid or a glucocorticoid. 
     
     
         20 . The method of  claim 9 , wherein the method further comprises administering an insulin sensitizing medication. 
     
     
         21 . The method of  claim 9 , wherein the method further comprises administering a vaccine or immunogens against androstenedione. 
     
     
         22 - 30 . (canceled)